TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: SUPRIYA · data 2026-11-02
Supriya Lifescience Limited
In plain words
Price: 21.9% below its 52-week high of ₹1,085.
Delivery: 43.3% of traded shares were kept for delivery over the last 10 sessions, against 43.1% over the last 60.
Latest results: a net profit of ₹24 cr for the quarter ended Jun 2026 (-30.9% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹873 cr |
| Net profit (last 12 months) | ₹198 cr |
| Sales growth, 3 years (yearly) | 21.2% |
| Profit growth, 3 years (yearly) | 32.5% |
At a glance
Promoters 68.3% (unchanged in a year), pledged 0.0%, institutions 11.9%.
P/E 34.4, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 19.1%, ROCE 22.3%, operating margin 29.7%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 32.5% and sales growth 21.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (19.1%).
- Healthy operating margin (29.7%).
- Profit grew 32.5% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
SUPRIYA Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹189.75 crore, up 30.8% YoY and down 31.4% QoQ.
Net profit was ₹24.04 crore, down 30.9% YoY and down 67.6% QoQ.
Operating margin was 25% (35.6% a year ago).
EPS was ₹2.99, down 30.8% YoY and down 67.6% QoQ.
SUPRIYA के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹189.75 करोड़; पिछले साल की तुलना में 30.8% की बढ़त, पिछली तिमाही की तुलना में 31.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹24.04 करोड़; पिछले साल की तुलना में 30.9% की गिरावट, पिछली तिमाही की तुलना में 67.6% की गिरावट।
ऑपरेटिंग मार्जिन: 25% (एक साल पहले 35.6%)।
EPS: ₹2.99; पिछले साल की तुलना में 30.8% की गिरावट, पिछली तिमाही की तुलना में 67.6% की गिरावट।
SUPRIYAના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹189.75 કરોડ; ગયા વર્ષની સરખામણીએ 30.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 31.4% ઘટાડો.
ચોખ્ખો નફો: ₹24.04 કરોડ; ગયા વર્ષની સરખામણીએ 30.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 67.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 25% (એક વર્ષ પહેલાં 35.6%).
EPS: ₹2.99; ગયા વર્ષની સરખામણીએ 30.8% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 67.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
9/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 43.5% over the last 20 sessions vs 38.3% in the 40 before (1.14x); shares delivered per day 0.51x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 4 Sept 26Dividend Dividend ₹1 (ex-date) +7.9% next session
- 13 Aug 26Results Q1 FY27 results: profit −30.9% YoY -4.7% next session
- 27 May 26Results Q4 FY26 results: profit +47.3% YoY +24.0% next session
- 9 Feb 26Results Q3 FY26 results: profit +6.2% YoY +2.6% next session
- 12 Nov 25Results Q2 FY26 results: profit +9.3% YoY +5.8% next session
- 4 Sept 25Dividend Dividend ₹1 (ex-date) -1.6% next session
- 13 Aug 25Results Q1 FY26 results: profit −22.1% YoY -0.1% next session
- 27 May 25Results Q4 FY25 results: profit +36.4% YoY -3.0% next session
- 24 Jan 25Results Q3 FY25 results: profit +57.0% YoY -9.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹190 cr | ₹24 cr | -30.9% | 25.0% | 2.99 |
| Mar 2026 | ₹277 cr | ₹74 cr | +47.3% | 35.3% | 9.22 |
| Dec 2025 | ₹206 cr | ₹50 cr | +6.2% | 34.9% | 6.17 |
| Sept 2025 | ₹200 cr | ₹50 cr | +9.3% | 36.4% | 6.27 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% |
| Foreign institutions (FII) | 6.44% | 6.19% | 5.16% | 5.20% |
| Domestic institutions (DII) | 5.47% | 5.30% | 5.70% | 5.01% |
| Mutual funds | 1.28% | 1.29% | 1.33% | 0.67% |
| Retail investors | 14.18% | 14.74% | 15.23% | 15.61% |
| Number of shareholders | 78,561 | 82,082 | 81,161 | 85,099 |
Common questions
What was Supriya Lifescience Limited's latest quarterly profit?
Supriya Lifescience Limited reported a net profit of ₹24 cr for the quarter ended Jun 2026 (-30.9% on the same quarter a year earlier), on revenue of ₹190 cr.
How much do promoters hold in Supriya Lifescience Limited?
Promoters held 68.30% of Supriya Lifescience Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Supriya Lifescience Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Supriya Lifescience Limited's P/E ratio?
About 34.4, based on the last 12 months' earnings and a price of ₹847.8 (data 2026-11-02).
What is the 52-week high and low of Supriya Lifescience Limited?
The 52-week high is ₹1,085 and the 52-week low is ₹545.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Supriya Lifescience Limited | ₹847.8 | ₹6,810 cr | 34.4 | — | 19.1% | 22.3% | 0 | +12.5% |
| Sanofi India Limited | ₹3,289.3 | ₹7,380 cr | 20.8 | — | 40.6% | 54.6% | 0.02 | -31.5% |
| Suven Life Sciences Limited | ₹262.15 | ₹7,293 cr | — | — | -78.8% | -80.8% | 0.03 | +35.2% |
| Bliss GVS Pharma Limited | ₹626 | ₹6,894 cr | 49.6 | — | 11.5% | 10.9% | 0.02 | +300.8% |
| Morepen Laboratories Limited | ₹107.69 | ₹6,230 cr | 31.3 | 4.3 | 7.9% | 6.2% | 0.17 | +123.1% |
| FDC Ltd. | ₹379.55 | ₹6,132 cr | 19.7 | 2.3 | 11.8% | 11.7% | 0.01 | -16.0% |
Compare SUPRIYA with SANOFI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SUPRIYA in TickerKhoj →